Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Declines By 50.0%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 22,521 shares, a decrease of 50.0% from the June 30th total of 45,019 shares. Based on an average daily volume of 33,926 shares, the short-interest ratio is presently 0.7 days. Currently, 0.1% of the shares of the stock are sold short.

China SXT Pharmaceuticals Trading Down 8.9%

Shares of NASDAQ SXTC traded down $0.01 during mid-day trading on Wednesday, hitting $0.05. 44,145,929 shares of the stock were exchanged, compared to its average volume of 6,209,868. The stock’s fifty day simple moving average is $1.97 and its two-hundred day simple moving average is $4.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94. China SXT Pharmaceuticals has a twelve month low of $0.05 and a twelve month high of $1,046.98.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its quarterly earnings data on Wednesday, July 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.26 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, July 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On China SXT Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SXTC. Virtu Financial LLC lifted its position in shares of China SXT Pharmaceuticals by 107.5% during the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of China SXT Pharmaceuticals in the third quarter valued at approximately $78,000. Finally, XTX Topco Ltd acquired a new stake in shares of China SXT Pharmaceuticals in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.